Avoid common mistakes on your manuscript.
Correction to: Endocrine (2023) 82:215–225
In this article, the mean absolute relative difference (MARD) for the rtCGM/Glunovo i3/Flash device in Table1, column MARD, was initially reported as 9.3%. The value has been rectified to 10.3% in this erratum.
Table S1. Characteristics of currently available CGM devices
CGM type/sensor | Reading period/sensor lifetime/transmitter lifetime | Calibrations (n/day) | Smartphone compatibility/ CSII integrated (SAP/AP) | MARD | Insertion site | % 15/15 mg/dl overalle | % 20/20 mg/dl overallf | Data management | Adjunctive use/non adjunctive use | Use in pregnancyi | Intended populations |
---|---|---|---|---|---|---|---|---|---|---|---|
rtCGM/Dexcom G6 | 10 days/10 days/ 3 months | 0 | Yes/Yes | 9% | Abdomen, arm, upper gluteusd | 83.3% | 93.9% | Clarity/Diasend/ Glooko | Non adjunctive use | Indicated | 2 years and older |
rtCGM/Dexcom G7 | 10 days/10 daysb (+12 h tolerance) | 0 | Yes/Yes | 8.2% | Abdomen, arm, upper gluteusd | 89.6%g | 95.3%g | Clarity/ Glooko | Non adjunctive use | Indicated | 2 years and older |
rtCGM/TouchCare A7+ | 10 days /10 days/ 12 months | 1 | Yes/Yes | 9% | Abdomen, upper gluteus | NA | NA | EasyView Pro | Non adjunctive use | Not specified | 2 years and older |
rtCGM/Eversense E3a | 180 days/180 days/12 months | 2/1c | Yes/No | 8.5% | Upper arm | 85.6% | 92.9% | Eversense DMS | Non adjunctive use | Not indicated | 18 years and older |
rtCGM/GlucoMen Day | 14 days/14 days/ 5 years | 1 | Yes/No | 9.6% | Abdomen | NA | NA | Glucolog/Diasend/ Glooko | Non adjunctive use | Indicated | 6 years and older |
rtCGM/Glunovo i3/Flash | 14 days/14 days/ 3 years | 0 | Yes/No | 10.3% | Abdomen | 79.31% | 89.71% | IrisHealthCare | Adjunctive use | Indicated | 2 years and older |
rtCGM/Guardian sensor 3 | 7 days/7 days/ 12 months | 2 | No/Yes | 9.1% | Abdomen, arm | 78.8% | 88.2% | Carelink | Adjunctive useh | Not specified | 2 years and older |
rtCGM/Guardian sensor 4 | 7 days/7 days/ 12 months | 0 | No/Yes | 10.6% | Abdomen, arm, upper gluteusd | NA | NA | Carelink | Non adjunctive use | Not specified | 2 years and older |
iCGM/Freestyle libre | 14 days/14 daysb | 0 | Yes/No | 9.2% | Arm | NA | NA | Libreview | Non adjunctive use | Indicated | 4 and older |
iCGM/Freestyle libre 2 | 14 days/14 daysb | 0 | Yes/No | 9.2% | Arm | 86.3% | 93.2% | Libreview | Non adjunctive use | Indicated | 4 and older |
rtCGM/Freestyle libre 3 | 14 days/14 daysb | 0 | Yes/No | 7.9% | Arm | 89.1% | 94.7% | Libreview | Non adjunctive use | Indicated | 4 and older |
The original article has been corrected.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1007/s12020-023-03473-w.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Maiorino, M.I., Buzzetti, R., Irace, C. et al. Correction: An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes. Endocrine 85, 456–457 (2024). https://doi.org/10.1007/s12020-023-03635-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-023-03635-w